BUSINESS
HCLTech lags estimates in Q4 but weaker growth guidance bigger disappointment
Analysts say HCLTech's weaker-than-expected FY25 growth guidance hints at near-term headwinds for the IT services company
BUSINESS
Gujarat State Petronet falls sharply from day's high as tariff cut triggers flurry of downgrades
The sharp tariff cut, which poses a threat to GSPL's financial performance, prompted brokerages such as Kotak, Nuvama, Emkay Global and ICICI Securities to downgrade the stock
BUSINESS
Can Dr Lal PathLabs, Metropolis brave competition from new-age diagnostic rivals?
New-age players, in spite of cutting down on discounts, are seeing significantly higher revenue growth than incumbents.
BUSINESS
Zydus Life gains over 3% on launch of bladder control drug
Incred Equities estimates Mirabegron to be a $75-80 million opportunity for Zydus Lifesciences, as the company also enjoys a 180-day exclusivity period
BUSINESS
IPO Market Action: 4 public issues to open for subscription with 4 SME listings lined up next week
The SME segment will remain busy with four companies making its market debut this week.
BUSINESS
Tata Communications stock falls for 8th straight day; brokerages see limited upside
Tata Communications' weak margin performance in Q4 turned out to be the biggest dampener for brokerages. Its EBITDA margin contracted to 18.6% in Q4, down from 22.6% in the year-ago period.
BUSINESS
Drug shortage in US at all-time high: Does it mean great times ahead for Indian generics makers?
The scarcity of several medications in the US presents Indian pharma players with a great chance to expand market share, regulatory hurdles and industry dynamics allowing.
BUSINESS
What drew MIT's investment arm to this small cap pharma company?
MIT's recent investment in Marksans Pharma underscores the small-cap's hidden gem status, fuelled by its strong presence in stable OTC markets and strategic growth initiatives, signalling promising prospects for revenue and profit expansion.
BUSINESS
Jefferies' target price on Bharti Hexacom stock screams 'ek saal me paisa double' for IPO investors
Jefferies initiated coverage on Bharti Hexacom with a 'buy' call and a price target of Rs 1,080. The stock gained 9 percent in intraday trading.
BUSINESS
Markets assessing the promise of policy continuity in BJP's manifesto
The BJP's 2024 manifesto paints a picture of economic acceleration and global prominence, drawing applause the Street amidst hopes of its positive impact on domestic equities.
BUSINESS
Another regulatory blow for Sun Pharma after Dadra unit tagged 'OAI' by US FDA, stock down
The official action indicated classification for the Dadra unit by FDA follows similar trouble at Sun Pharma's Halol and Mohali facilities recently, which hit generic sales
BUSINESS
QSR is missing the spice of demand uptick, while cost of adding stores stays high
Kotak chose Sapphire Foods as its preferred pick within the QSR space given its reasonable valuation and lower risk to earnings, followed by Devyani International.
BUSINESS
Bandhan Bank tanks 9% after CEO decides to step down
Concerned over the uncertainty, Jefferies slashed the price target for Bandhan Bank by over 41 percent to Rs 170
BUSINESS
Analyst Call Tracker: Global specialty, strong India outlook steer optimism for Sun Pharma
Analysts expect Sun Pharma's strong growth in global specialty thanks to new launches and a resilient standing in the domestic market to be key drivers for the drugmaker.
BUSINESS
Chemical stocks to face near-term pressure on demand slowdown but capex to aid future growth
While the near term pain for chemical stocks is expected to continue due to a demand slowdown and pricing pressure in the sector, the long-term outlook looks bright amid expectations of a strong recovery and capex plans.
BUSINESS
Wockhardt's R&D prowess attracts marquee investors Madhusudan Kela, Prashant Jain
Wockhardt has two molecules — Nafithromycin (WCK 4873) for treating pneumonia and WCK 5222 for urinary tract infection, in development phases, with launched lined up for FY25 and FY26
BUSINESS
IndiGo shares fly to record high as brokerages foresee strong growth, raise price targets
After an analysts' meet on March 22, brokerages such as like UBS Securities, Kotak Institutional Equities and Motilal Oswal Financial Services expects strong growth for IndiGo on the back of its expansion plans as well as robust growth in the domestic air travel sector
BUSINESS
Commodities cycle has bottomed out, decadal opportunity in energy, power: Sandeep Tandon
The Quant Mutual Fund Founder & CEO sees listed commodities, metals, pharma, cement, and infra as pockets that offer value at the current juncture
BUSINESS
Copper to shine brighter in the days ahead, believes Jefferies
Just this week, the copper market awoke from a year-long slumber as the metal's price surged on the London Metal Exchange (LME) to an eleven month high of $8,976.50 per metric ton.
BUSINESS
Grasim's discount pricing for Birla Opus may be code red for Asian Paints
Jefferies sees downside risks for industry leader Asian Paints as new entrant Grasim offers a discount of around 5 percent in its paints brand, Birla Opus.
BUSINESS
MC Explains | What is the US Fed dot plot and why does the market watch it so closely?
Comparing dot plots over FOMC policy meetings helps analysts understand how the Federal Reserve’s thinking is shifting over time.
BUSINESS
BSE shares soar 8% on Investec 'buy' upgrade, 38% upside seen
Strong traction in equity derivatives volumes, expectations of market share gains and stabilisation in metrics for BSE are the factors citied by Investec for the upgrade
BUSINESS
Rising Bharat Summit 2024: How India's bull case looks to top market investors
Top investors are betting on India as a multi-decade story driven by a growing middle class, financialisation of savings, robust consumption cycle, supportive government policies.
BUSINESS
Can NPCI's nod to Paytm's UPI business ease its misery?
Some brokerages now see rosier prospects for Paytm after the doom-and-gloom of reports in the wake of the RBI diktat against Paytm Payments Bank.
